Lymphoma, as a malignant disorder, increases the risk of thrombotic complications and those complications significantly affect morbidity of patients. Additionally, thromboembolic events are one of the leading causes of death among patients with malignancy in general.
This review emphasizes several practice points in managing lymphoma patients with thromboembolic complications: • Thromboprophylaxis in lymphoma patients are underused. • Use of anticoagulation drugs in patients with lymphoma requires monitoring of blood count, kidney function, as well as drug–drug interactions. • The Thrombosis Lymphoma (ThroLy) score has been shown to be more precise for lymphoma patients than any other available score targeting thrombosis risk in cancer patients developed so far. • Use of direct oral anticoagulants in lymphoma patients is still under debate and requires a multidisciplinary approach.
The purpose of this article is to present a comprehensive view of management of lymphoma patients with thromboembolic complications or an increased risk for thromboembolism. Previously developed ThroLy score served as a perfect basis for discussing all aspects of this particular topic. Also, this article showed the importance and necessity of multidisciplinary approach, patient's full compliance, as well as careful monitoring of potential chemotherapy-drug toxicity.Dr. Srdjan Nikolovski, MD
Blood Rev 2018 03 31;32(2):144-158. Epub 2017 Oct 31.
Clinic for Hematology, Clinical Centre Serbia, Belgrade, Serbia; Medical Faculty, University of Belgrade, Belgrade, Serbia.
Download full-text PDF